Testicular cancer

Liang Cheng, Peter Albers, Daniel M. Berney, Darren R. Feldman, Gedske Daugaard, Timothy Gilligan, Leendert H.J. Looijenga

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Testicular cancer is the most common malignancy among men between 14 and 44 years of age, and its incidence has risen over the past two decades in Western countries. Both genetic and environmental factors contribute to the development of testicular cancer, for which cryptorchidism is the most common risk factor. Progress has been made in our understanding of the disease since the initial description of carcinoma in situ of the testis in 1972 (now referred to as germ cell neoplasia in situ), which has led to improved treatment options. The combination of surgery and cisplatin-based chemotherapy has resulted in a cure rate of >90% in patients with testicular cancer, although some patients become refractory to chemotherapy or have a late relapse; an improved understanding of the molecular determinants underlying tumour sensitivity and resistance may lead to the development of novel therapies for these patients. This Primer provides an overview of the biology, epidemiology, diagnosis and current treatment guidelines for testicular cancer, with a focus on germ cell tumours. We also outline areas for future research and what to expect in the next decade for testicular cancer.

Original languageEnglish (US)
Article number29
JournalNature Reviews Disease Primers
Volume4
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Testicular Neoplasms
Drug Therapy
Neoplasms
Cryptorchidism
Germ Cell and Embryonal Neoplasms
Carcinoma in Situ
Germ Cells
Cisplatin
Testis
Epidemiology
Therapeutics
Guidelines
Recurrence
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018). Testicular cancer. Nature Reviews Disease Primers, 4(1), [29]. https://doi.org/10.1038/s41572-018-0029-0

Testicular cancer. / Cheng, Liang; Albers, Peter; Berney, Daniel M.; Feldman, Darren R.; Daugaard, Gedske; Gilligan, Timothy; Looijenga, Leendert H.J.

In: Nature Reviews Disease Primers, Vol. 4, No. 1, 29, 01.12.2018.

Research output: Contribution to journalReview article

Cheng, L, Albers, P, Berney, DM, Feldman, DR, Daugaard, G, Gilligan, T & Looijenga, LHJ 2018, 'Testicular cancer', Nature Reviews Disease Primers, vol. 4, no. 1, 29. https://doi.org/10.1038/s41572-018-0029-0
Cheng L, Albers P, Berney DM, Feldman DR, Daugaard G, Gilligan T et al. Testicular cancer. Nature Reviews Disease Primers. 2018 Dec 1;4(1). 29. https://doi.org/10.1038/s41572-018-0029-0
Cheng, Liang ; Albers, Peter ; Berney, Daniel M. ; Feldman, Darren R. ; Daugaard, Gedske ; Gilligan, Timothy ; Looijenga, Leendert H.J. / Testicular cancer. In: Nature Reviews Disease Primers. 2018 ; Vol. 4, No. 1.
@article{ce3bb17ea55e487584d1eaa412f1808b,
title = "Testicular cancer",
abstract = "Testicular cancer is the most common malignancy among men between 14 and 44 years of age, and its incidence has risen over the past two decades in Western countries. Both genetic and environmental factors contribute to the development of testicular cancer, for which cryptorchidism is the most common risk factor. Progress has been made in our understanding of the disease since the initial description of carcinoma in situ of the testis in 1972 (now referred to as germ cell neoplasia in situ), which has led to improved treatment options. The combination of surgery and cisplatin-based chemotherapy has resulted in a cure rate of >90{\%} in patients with testicular cancer, although some patients become refractory to chemotherapy or have a late relapse; an improved understanding of the molecular determinants underlying tumour sensitivity and resistance may lead to the development of novel therapies for these patients. This Primer provides an overview of the biology, epidemiology, diagnosis and current treatment guidelines for testicular cancer, with a focus on germ cell tumours. We also outline areas for future research and what to expect in the next decade for testicular cancer.",
author = "Liang Cheng and Peter Albers and Berney, {Daniel M.} and Feldman, {Darren R.} and Gedske Daugaard and Timothy Gilligan and Looijenga, {Leendert H.J.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41572-018-0029-0",
language = "English (US)",
volume = "4",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Testicular cancer

AU - Cheng, Liang

AU - Albers, Peter

AU - Berney, Daniel M.

AU - Feldman, Darren R.

AU - Daugaard, Gedske

AU - Gilligan, Timothy

AU - Looijenga, Leendert H.J.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Testicular cancer is the most common malignancy among men between 14 and 44 years of age, and its incidence has risen over the past two decades in Western countries. Both genetic and environmental factors contribute to the development of testicular cancer, for which cryptorchidism is the most common risk factor. Progress has been made in our understanding of the disease since the initial description of carcinoma in situ of the testis in 1972 (now referred to as germ cell neoplasia in situ), which has led to improved treatment options. The combination of surgery and cisplatin-based chemotherapy has resulted in a cure rate of >90% in patients with testicular cancer, although some patients become refractory to chemotherapy or have a late relapse; an improved understanding of the molecular determinants underlying tumour sensitivity and resistance may lead to the development of novel therapies for these patients. This Primer provides an overview of the biology, epidemiology, diagnosis and current treatment guidelines for testicular cancer, with a focus on germ cell tumours. We also outline areas for future research and what to expect in the next decade for testicular cancer.

AB - Testicular cancer is the most common malignancy among men between 14 and 44 years of age, and its incidence has risen over the past two decades in Western countries. Both genetic and environmental factors contribute to the development of testicular cancer, for which cryptorchidism is the most common risk factor. Progress has been made in our understanding of the disease since the initial description of carcinoma in situ of the testis in 1972 (now referred to as germ cell neoplasia in situ), which has led to improved treatment options. The combination of surgery and cisplatin-based chemotherapy has resulted in a cure rate of >90% in patients with testicular cancer, although some patients become refractory to chemotherapy or have a late relapse; an improved understanding of the molecular determinants underlying tumour sensitivity and resistance may lead to the development of novel therapies for these patients. This Primer provides an overview of the biology, epidemiology, diagnosis and current treatment guidelines for testicular cancer, with a focus on germ cell tumours. We also outline areas for future research and what to expect in the next decade for testicular cancer.

UR - http://www.scopus.com/inward/record.url?scp=85054452066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054452066&partnerID=8YFLogxK

U2 - 10.1038/s41572-018-0029-0

DO - 10.1038/s41572-018-0029-0

M3 - Review article

C2 - 30291251

AN - SCOPUS:85054452066

VL - 4

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

IS - 1

M1 - 29

ER -